Vikram Purohit
Stock Analyst at Morgan Stanley
(0.88)
# 3,756
Out of 4,876 analysts
169
Total ratings
28.33%
Success rate
-10.34%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Maintains: Equal-Weight | $8 → $5 | $5.40 | -7.41% | 3 | Jun 16, 2025 | |
| HALO Halozyme Therapeutics | Downgrades: Equal-Weight | $73 → $62 | $52.53 | +18.03% | 7 | May 14, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $173.17 | +44.37% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $70.81 | -8.21% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $102.57 | +85.24% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $10.15 | +244.83% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.88 | +84.43% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $20.73 | +49.54% | 2 | Sep 11, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $2.71 | +158.30% | 1 | Jul 3, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $7.18 | +122.84% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.66 | +1,027.82% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $9.28 | +137.07% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $14.40 | -30.56% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.45 | +144.90% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $8.75 | +380.00% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $1.25 | +1,700.00% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $45.71 | -10.30% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $22.17 | +80.42% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $0.72 | +1,698.31% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $20.49 | +85.46% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.42 | +75.13% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $10.73 | -6.80% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $29.64 | -76.38% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.48 | +1,386.49% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $9.21 | +117.16% | 2 | Aug 5, 2020 |
Recursion Pharmaceuticals
Jun 16, 2025
Maintains: Equal-Weight
Price Target: $8 → $5
Current: $5.40
Upside: -7.41%
Halozyme Therapeutics
May 14, 2025
Downgrades: Equal-Weight
Price Target: $73 → $62
Current: $52.53
Upside: +18.03%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $173.17
Upside: +44.37%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $70.81
Upside: -8.21%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $102.57
Upside: +85.24%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $10.15
Upside: +244.83%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.88
Upside: +84.43%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $20.73
Upside: +49.54%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $2.71
Upside: +158.30%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $7.18
Upside: +122.84%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $2.66
Upside: +1,027.82%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $9.28
Upside: +137.07%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $14.40
Upside: -30.56%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.45
Upside: +144.90%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $8.75
Upside: +380.00%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $1.25
Upside: +1,700.00%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $45.71
Upside: -10.30%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $22.17
Upside: +80.42%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $0.72
Upside: +1,698.31%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $20.49
Upside: +85.46%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.42
Upside: +75.13%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $10.73
Upside: -6.80%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $29.64
Upside: -76.38%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.48
Upside: +1,386.49%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $9.21
Upside: +117.16%